Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repare Therapeutics Inc RPTX

Healthcare Biotechnology
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its... see more

Recent & Breaking News (NDAQ:RPTX)

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Business Wire November 7, 2023

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Business Wire November 6, 2023

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Business Wire October 13, 2023

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Business Wire October 3, 2023

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Business Wire September 19, 2023

Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Business Wire September 6, 2023

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Business Wire August 9, 2023

Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

Business Wire June 8, 2023

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Business Wire June 7, 2023

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

Business Wire June 6, 2023

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights

Business Wire June 2, 2023

Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 22, 2023

Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Business Wire May 9, 2023

Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

Business Wire April 28, 2023

Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting

Business Wire April 18, 2023

Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Business Wire March 14, 2023

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 28, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

Newsfile February 18, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX

PR Newswire February 13, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

Newsfile February 10, 2023